Weight gain associated with the α2a-adrenergic receptor -1291 C/G polymorphism and olanzapine treatment

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 141, Issue 4, 2006, Pages 394-397

  Park, Young Min ^a   Chung, Young Cho ^a   Lee, Seung Hwan ^a   Lee, Kang Joon ^a   Kim, Hyun ^a   Byun, Young Chan ^b   Lim, Se Won ^c   Paik, Jong Woo ^c   Lee, Heon Jeong ^c,d  

^a Inje University College of Medicine   (South Korea)

^b Eumsung Mental Hospital   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d Korea University College of Medicine   (South Korea)

Author keywords

2a adrenergic receptor; Olanzapine; Polymorphisms; Schizophrenia; Weight gain

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; CYTOSINE; GUANINE; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; AGED; ARTICLE; BODY HEIGHT; CONTROLLED STUDY; FEEDING BEHAVIOR; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIPOLYSIS; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; SCHIZOPHRENIA; WEIGHT GAIN;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KOREA; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC, ALPHA-2; SCHIZOPHRENIA; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 33745013199     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30311     Document Type: Article

References (31)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. 1999. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 156:1686-1696.
2. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders: DSM-IV, 4th edition. Washington DC: American Psychiatric Association.
3. Arner P. 1999. Catecholamine-induced lipolysis in obesity. Int J Obes Relat Metab Disord 23:10-13.
4. Basile VS, Masellis M, De Luca V, Meltzer HY, Kennedy JL. 2002. 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 360:1790-1791.
5. Casey DE, Zorn SH. 2001. The pharmacology of weight gain with antipsychotics. J Clin Psychiatry 62:4-10.
6. Castan I, Valet P, Larrouy D, Voisin T, Remaury A, Daviaud D, Laburthe M, Lafontan M. 1993. Distribution of PYY receptors in human fat cells: An antilipolytic system alongside the alpha 2-adrenergic system. Am J Physiol 265:74-80.
7. Ellingrod VL, Perry PJ, Ringold JC, Lund BC, Bever-Stille K, Fleming P, Holman TL, Miller D. 2005. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet Part B 134B:76-78.
8. Hamann A, Brieske C, Tafel J, Buttron P, Schwarzloh B, Munzberg H, Hinney A, Mayer H, Siegfried W, Hebebrand J, Greten H, Algenstaedt P, Ziegler R. 2001. Identification of a deletion variant in the gene encoding the human alpha(2A)-adrenergic receptor. Eur J Endocrinol 144:291-295.
9. Han OS, Hong JP. 2000. Structured clinical interview for DSM-IV Axis I disorder-Korean version. Seoul: Hana Medical Publishing.
10. Heinonen P, Koulu M, Pesonen U, Karvonen MK, Rissanen A, Laakso M, Valve R, Uusitupa M, Scheinin M. 1999. Identification of a three-amino acid deletion in the alpha2B-adrenergic receptor that is associated with reduced basal metabolic rate in obese subjects. J Clin Endocrinol Metab 84:2429-2433.
11. Hellstrom L, Rossner S, Hagstrom-Toft E, Reynisdottir S. 1997. Lipolytic catecholamine resistance linked to alpha 2-adrenoceptor sensitivity-A metabolic predictor of weight loss in obese subjects. Int J Obes Relat Metab Disord 21:314-320.
12. Jibson MD, Tandon R. 1998. New atypical antipsychotic medications. J Psychiatr Res 32:215-228.
13. Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, Revicki D, Buchanan RW. 2002. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 59:1021-1026.
14. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL. 2003. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-526.
15. Lafontan M, Berlan M. 1993. Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res 34:1057-1091.
16. Lambert B, Tafesse E, Carson WH. 2003. Antipsychotic-indued hyperlipidemia among people with schizophrenia. Presented at the 156th annual meeting of the American Psychiatric Association, 17-22.
17. Lario S, Calls J, Cases A, Oriola J, Torras A, Rivera F. 1997. MspI identifies a biallelic polymorphism in the promoter region of the alpha 2A-adrenergic receptor gene. Clin Genet 51:129-130.
18. Loos RJ, Rankinen T. 2005. Gene-diet interactions on body weight changes. J Am Diet Assoc 105:829-834.
19. Mauriege P, Galitzky J, Berlan M, Lafontan M. 1987. Heterogeneous distribution of beta and alpha-2 adrenoceptor binding sites in human fat cells from various fat deposits: Functional consequences. Eur J Clin Invest 17:156-165.
20. Meyer JM. 2001. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 21:369-374.
21. Miller del D, Ellingrod VL, Holman TL, Buckley PF, Arndt S. 2005. Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. Am J Med Genet Part B 133B:97-100.
22. Nasrallah H. 2003. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 28:83-96.
23. Reynolds GP, Zhang ZJ, Zhang XB. 2002. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359:2086-2087.
24. Reynolds GP, Zhang ZJ, Zhang XB. 2003. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 160:677-679.
25. Snyder EE, Walts B, Perusse L, Chagnon YC, Weisnagel SJ, Rankinen T, Bouchard C. 2003. The human obesity gene map: The 2003 update. Obes Res 12:369-439.
26. Stich V, de Glisezinski I, Crampes F, Suljkovicova H, Galitzky J, Riviere D, Hejnova J, Lafontan M, Berlan M. 1999. Activation of antilipolytic alpha(2)-adrenergic receptors by epinephrine during exercise in human adipose tissue. Am J Physiol 277:R1076-R1083.
27. Stich V, De Glisezinski I, Crampes F, Hejnova J, Cottet-Emard JM, Galitzky J, Lafontan M, Riviere D, Berlan M. 2000. Activation of alpha(2)-adrenergic receptors impairs exercise-induced lipolysis in SCAT of obese subjects. Am J Physiol Regul Integr Comp Physiol 279: R499-R504.
28. Taylor DM, McAskill R. 2000. Atypical antipsychotics and weight gain-A systematic review. Acta Psychiatr Scand 101:416-432.
29. Tsai SJ, Hong CJ, Yu YW, Lin CH. 2002. -759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 360:1790.
30. Wang YC, Bai YM, Chen JY, Lin CC, Lai IC, Liou YJ. 2005. Polymorphism of the adrenergic receptor alpha 2a -1291C>G genetic variation and clozapine-induced weight gain. J Neural Transm 112:1463-1468.
31. Wellman PJ, Davies BT, Morien A, et al. 1993. Modulation of feeding by hypothalamic paraventricular nucleus alpha 1- and alpha 2-adrenergic receptors. Life Sci 53:669-679.